IL6 and metabolic disease: Moreover, it was shown that even in the absence of diabetes or other metabolic disorders both inflammatory mechanisms and pro-inflammatory mediators (tumor necrosis factor-alpha or interleukin-6) have been involved in the pathogenesis of IR when pro-inflammatory cytokines develop inflammation through reactive oxygen species (ROS) and oxidative stress pathways [35].